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Abstract
Purpose—Activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL) is an aggressive,
poorly chemoresponsive lymphoid malignancy characterized by constitutive canonical NF-κB
activity that promotes lymphomagenesis and chemotherapy resistance via over-expression of anti-
apoptotic NF-κB target genes. Inhibition of the canonical NF-κB pathway may therefore have
therapeutic relevance in ABC-DLBCL. Here we set out to determine whether dogs with
spontaneous DLBCL have comparative aberrant constitutive NF-κB activity and to determine the
therapeutic relevance of NF-κB inhibition in dogs with relapsed, resistant DLBCL.
Experimental Design—Canonical NF-κB activity was evaluated by electrophoretic mobility
shift assays and immunoblot analyses, and NF-κB target gene expression was measured by qRT-
PCR. Primary malignant canine B lymphocytes were treated with the selective IKK complex
inhibitor Nemo Binding Domain (NBD) peptide, and evaluated for NF-κB activity and apoptosis.
NBD peptide was administered intra-nodally to dogs with relapsed B-cell lymphoma and NF-κB
target gene expression and tumor burden were evaluated pre and post treatment.
Results—Constitutive canonical NF-κB activity and increased NF-κB target gene expression
was detected in primary DLBCL tissue. NBD peptide inhibited this activity and induced apoptosis
of primary malignant B cells in vitro. Intra-tumoral injections of NBD peptide to dogs with
relapsed DLBCL inhibited NF-κB target gene expression and reduced tumor burden.
Conclusions—This work shows that dogs with spontaneous DLBCL represent a clinically
relevant, spontaneous, large animal model for human ABC-DLBCL and demonstrates the
therapeutic relevance of NF-κB inhibition in the treatment of ABC-DLBCL. These results have
important translational relevance for ABC-DLBCL treatment in human patients.
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Introduction
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common adult lymphoid malignancy
with approximately 30,000 new cases diagnosed each year in the United States (1, 2). Gene
expression profiling has revealed the presence of at least three subtypes of DLBCL,
Activated B-Cell (ABC-DLBCL), Germinal Center B-Cell (GBC-DLBCL) and Primary
Mediastinal B-Cell Lymphoma (PMBL), that have distinct molecular signatures and
different clinical outcomes (1, 3). ABC-DLBCL is the most aggressive subtype and is less
responsive to conventional multi-agent chemotherapy than GCB-DLBCL and PMBL. Even
with the addition of Rituximab, the overall survival for patients with ABC-DLBCL is 47%
(4).
ABC-DLBCL is characterized by the presence of constitutive canonical NF-κB activity that
drives expression of NF-κB target genes which promote lymphocyte proliferation (e.g.
Cyclin D1 and D2) and inhibit apoptosis (e.g. Bcl-2, Bcl-xl, A1, c-FLIP, and XIAP) (5, 6).
Aberrant canonical NF-κB activity contributes to lymphomagenesis and chemoresistance by
promoting malignant cell survival and proliferation (7, 8). In health, NF-κB activation is
highly regulated. NF-κB dimers are held inactive in the cytoplasm through their association
with inhibitory IκB family members (9). Engagement of cell surface receptors by many
different infectious and inflammatory stimuli leads to phosphorylation and activation of the
IKK complex, which phosphorylates IκBα and targets it for ubiquitination and proteosomal
degradation. This allows NF-κB dimers to translocate to the nucleus where they bind to
target gene promoters and enhancers and initiate transcription (8). Somatic activating
mutations in genes encoding regulatory proteins upstream of the IKK complex have been
identified in patients with ABC-DLBCL and lead to constitutive phosphorylation and
activation of the IKK complex (5, 10, 11). Constitutive, canonical NF-κB activity is
essential for ABC-DLBCL cell survival (3, 7) and inhibition of this pathway with small
molecule inhibitors of IKK, IκBα super-repressors, proteosome inhibitors, or inhibitors
upstream of the IKK complex promotes cell cycle arrest, chemotherapeutic sensitivity and
apoptosis in ABC-DLBCL cell lines (3, 7, 12). Taken together, these findings suggest that
targeted inhibition of aberrant NF-κB activity represents a promising therapeutic strategy for
patients with primary or relapsed ABC-DLBCL.
The high-quality draft genome sequence of the dog has revealed its close phylogenetic
relationship with man, emphasizing the potential benefit of canine models in identifying
disease genes and evaluating response to novel therapies (13–16). In particular, the dog is
being increasingly recognized as a clinically relevant, spontaneous large animal model for
human Non Hodgkin’s Lymphoma (NHL) (17–19). NHL is the most common, spontaneous,
hematopoietic malignancy in dogs, with an annual incidence of 30/100,000 (20). DLBCL is
the most common subtype of canine NHL and shares similar biologic, behavioral, molecular
and genetic characteristics with DLBCL in humans (17, 20–22). Dogs with DLBCL are
treated with the same cytotoxic agents used in human DLBCL patients that inhibit cell
division and induce apoptosis. However, as in human patients, clinical remission is not
maintained and 85–90% of canine patients relapse with lethal, drug-resistant lymphoma
within 6 to 9 months of initial diagnosis and treatment (19, 23).
NEMO Binding Domain (NBD) peptide is a selective inhibitor of the IKK complex that
consists of 11 amino acids located at the carboxy terminus of the catalytic IKKβ subunit that
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binds to the scaffold protein NF-κB Essential Modulator (NEMO) (24). The core of six
amino acids in the NBD is also present in IKKα and facilitates its association with NEMO
(24–26). NBD peptide inhibits the interaction of both IKKα and IKKβ with NEMO and
prevents assembly of the IKK complex (25). Fusion of NBD peptide to protein transduction
domains, such as that within the drosophila antennapedia protein enables it to enter cells and
effectively inhibit canonical NF-κB activation in response to TNFα, lipopolysaccharide and
Toll-Like Receptor ligation (24, 25, 27). Systemic administration of NBD peptide results in
potent anti-inflammatory effects in animal models of inflammation (24, 28–32). NBD
peptide also inhibits constitutive NF-κB activity in tumor cell lines, including pancreatic
carcinoma, squamous cell carcinoma, melanoma, cutaneous T cell lymphoma and mantel
cell lymphoma, and sensitizes these cells to TRAIL or TNFα-induced apoptosis (33–37).
Furthermore, NBD peptide inhibits NF-κB activation that occurs in response to DNA
damage induced by cytotoxic chemotherapeutics (38). Taken together, these findings
suggest that targeted inhibition of canonical NF-κB activity using NBD peptide may
represent an effective therapeutic strategy in patients with ABC-DLBCL.
Before evaluating the therapeutic effects of NBD peptide in human patients with ABC-
DLBCL, we performed studies to evaluate its ability to inhibit constitutive NF-κB activity in
dogs with spontaneous B-cell lymphoma. We show that constitutive canonical NF-κB
activity occurs in the malignant lymph nodes of dogs with DLBCL and that this is associated
with over-expression of anti-apoptotic NF-κB target genes. We demonstrate that NBD
peptide inhibits constitutive NF-κB activity and induces apoptosis of canine malignant B
cells in vitro. Furthermore, we show that administration of NBD peptide to dogs with
relapsed B-cell lymphoma inhibits the expression of NF-κB target genes and leads to a
reduction in tumor burden. These findings provide proof of concept that NBD peptide can
inhibit constitutive NF-κB activity in a clinically relevant spontaneous canine model of
DLBCL and begin to pave the way for phased clinical trials in humans with ABC-DLBCL.
Materials and methods
Cells and Reagents
Canine lymphocytes were cultured in complete RPMI media containing 10% FBS. The
human GCB-DLBCL cell line SUDHL-6 was maintained in complete RPMI media, and the
human ABC-DLBCL cell line OCI-Ly10 was maintained in complete Iscove’s modified
essential medium (IMDM) containing 20% FBS. Cell lines were obtained from Dr. Anne
Novak (Mayo Clinic Cancer Center, Rochester, Mn). Malignant lymph node samples were
collected from dogs with either primary or relapsed DLBCL following approval from the
University of Pennsylvania’s Institutional Animal Care and Use Committee. The
histopathological diagnosis of DLBCL and the cytological diagnosis of large B cell
lymphoma were made by board certified veterinary pathologists (M.G., and A.D., see
acknowledgements) and by a board certified clinical pathologist (R.P.) respectively. NBD
peptide was synthesized and purified by Dr. James I. Elliott (at the Howard Hughes Medical
Institute Biopolymer-Keck Foundation Biotechnology Resource Laboratory, Yale
University, New Haven, CT) using standard tertbutoxycarbonyl (t-Boc) chemistry, cleavage
with hydrofluoric acid, and purification by reversed-phase HPLC (26). TNFα was purchased
from Sigma-Aldrich (Saint Louis, MO).
Western Blot Analyses
Cells were lysed in 50 mM Tris-HCL containing 1% NP-40, 150 mM NaCl, 2.5 mM EDTA,
5% glycerol, a 1:50 dilution of Protease Inhibitor Cocktail and 1:50 dilutions of Phosphatase
Inhibitor Cocktails 2 and 3 (Sigma-Aldrich). Protein concentrations were determined by
micro BCA assay (Thermo Scientific, Rockford, IL). Proteins were separated by SDS-
Gaurnier-Hausser et al. Page 3













PAGE (10%) and transferred to PVDF membrane. Membranes were probed with polyclonal
rabbit anti-human antibodies against phospho-IKKα/β (16A6), pan IKKβ (L570), phospho-
IκBα (14D4) andβ-actin (4967) (Cell Signaling, Danvers, MA) or rabbit anti-human pan
IκBα (C-21) (SantaCruz Biotechnology, Santa Cruz). An HRP-conjugated donkey anti-
rabbit IgG was used as the secondary detection antibody (Amersham, Piscataway, NJ). Blots
were developed using ECL Plus (Amersham, Piscataway, NJ) or SuperSignal West Femto
(Thermo Scientific, Rockford, IL).
Electrophoretic Mobility Shift Assay (EMSA)
Whole cell extracts of malignant canine lymphocytes were prepared as previously described
(26). EMSAs were performed using 5μg protein extract and a palindromic NF-κB binding
sequence probe (Santa Cruz Biotechnology) as previously described (26). EMSA supershift
assays were performed using 10μg of protein extract and polyclonal rabbit anti-human p65
(sc-109X), p50 (sc-114X) and c-Rel (sc-70X) antibodies or control rabbit IgG (sc-2027)
(Santa Cruz Biotechnology).
Quantitative Reverse Transcription PCR (qRT-PCR)
Total RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Valencia, CA).
Reverse transcription was performed using random hexamers and Superscript II reverse
transcriptase (Invitrogen Corp., Carlsbad. CA, USA). Transcript sequences for canine A1, c-
FLIP, Cyclin D1 and IκBα were obtained from the NCBI
(http://www.ncbi.nih.gov/Genbank) and were analyzed for secondary DNA structure using
M-Fold (http://frontend.bioinfo.rpi.edu/applications/mfold/cgi-bin/dna-form1.cgi). Primers
were designed using Primer 3 software (http://frodo.wi.mit.edu/primer3/) with the maximum
self-complementarity score set at 5 and the maximum 3 self-complementarity score set to 0
to minimize primer-dimer formation (Table 1). Primer sequences for canine Bcl-2, XIAP
and β-actin have been previously described (39). Quantitative RT-PCR was performed using
SYBR Green (Fermentas, Glen Burnie, Maryland). Samples were run in triplicate using
standard conditions on an ABI 7500 sequence detector (Applied Biosystems, Carlsbad, CA)
and data were analyzed using β-actin as an endogenous control. Dissociation curves were
performed after each experiment to confirm the specificity of product amplification.
Immunohistochemistry
Immunohistochemical analysis was performed on formalin fixed, paraffin-embedded tissue
sections of lymph nodes from healthy dogs and dogs with DLBCL. Sections were
deparaffinized in xylene, rehydrated and boiled in sodium citrate buffer to unmask antigens.
Endogenous peroxidase was blocked with 3% hydrogen peroxide. Immunohistochemistry
was performed using a rabbit anti-human p65 antibody (C22B4) (Cell Signaling, Danvers,
MA) or rabbit isotype control (sc-2027) (Santa Cruz Biotechnology) and the Vectastain Elite
ABC Kit (Vector Laboratories, Burlingame, CA). Sections were developed using 3′,3′
diaminobinzidine (DAB) and counterstained with hematoxylin. Slides were viewed using a
Nikon E600 infinity corrected upright microscope. Bright field images were acquired using
a Nikon Digital Sight DS-Fi1 color camera using NIS-Element BR3.0 for image analysis.
In Vitro NBD Peptide Treatment of Malignant B Lymphocytes
Freshly isolated or cryopreserved malignant lymphocytes from lymph nodes of dogs with
DLBCL were seeded at 4 × 106 cells/ml and treated with 100μm of either NBD or mutant
peptide in DMSO. After 12h, whole cell extracts were evaluated by immunoblot for
canonical NF-κB activity as described above, and for apoptosis by flow cytometry. The
human ABC- and GCB-DLBCL cell lines OCI-Ly10 and SUDHL-6, were seeded at 0.5 ×
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106 cells/ml and treated with 0, 25μM or 50μM NBD peptide. After 24 hours, cell death was
evaluated by Trypan Blue.
Flow Cytometry
Detection of apoptotic cell death was performed using the PE Annexin-V Apoptosis
Detection Kit (BD Biosciences, San Jose, CA). Cells were acquired on a FACSCalibur
cytometer (BD Biosciences) and analyzed using TreeStar FlowJo software.
Immunophenotyping of primary lymphoma cells was performed using the following
antibodies: FITC conjugated rat anti-canine CD3 (Serotec, Raleigh, NC), APC conjugated
mouse anti-human CD79a (BD Pharmingen, San Diego, CA) and mouse anti-canine CD21-
like molecule (Serotec, Raleigh, NC). A FITC-labeled goat anti-mouse IgG secondary
antibody was used to detect anti-CD21 antibody. For CD79a staining, cells were fixed with
1% paraformaldehyde and then permeabilized with 0.1% saponin prior to staining.
Pilot Trial
All in vivo studies were performed following approval from the University of
Pennsylvania’s Institutional Animal Care and Use Committee and the University of
Pennsylvania School of Veterinary Medicine Clinical Review Board. Client-owned dogs
were enrolled with the following inclusion criteria: 1) cytological confirmation of relapsed
large B-cell lymphoma, 2) stage III-V, substage a, with at least 1 set of bilateral, enlarged,
measurable, malignant lymph nodes, 3) life expectancy of greater than 1 month, 4) no
concurrent systemic disease, 5) adequate hematologic, renal and hepatic function and 6) the
presence of constitutive NF-κB activity within malignant lymph nodes as determined by
EMSA. All dogs enrolled in the pilot trial had been previously treated with a range of rescue
chemotherapeutic agents including L-asparaginase, cyclophosphamide, vincristine,
prednisone, lomustine, doxorubicin, mechlorethamine, procarbazine, dacarbazine and total
body irradiation. Signed informed consent was obtained from all owners before entry into
the study. Baseline evaluation included a complete medical history, full clinical
examination, complete blood count (CBC), chemistry screen (CS) and urinalysis, malignant
lymph node cytology and flow cytometric immunophenotyping using a basic panel of
antibodies including CD3, CD21 and CD79a. Eligible dogs received either 5 or 10mg NBD
peptide/100g malignant lymph node mass. Node mass was calculated based on two
dimension caliper measurements which were averaged and considered the diameter of the
lymph node sphere. Volume was determined based on V=2/3πr3. Based on our previous
assessments, 1cm3 of malignant lymph node mass is equivalent to ~379mg. Peptide was
injected directly into one malignant node and the same node was biopsied 24 hours later.
qRT-PCR for NF-κB target gene expression was performed on node tissue taken 24 hours
post NBD peptide treatment and was normalized to values obtained pre NBD peptide. No
control dogs were included in this pilot study. Following the post treatment biopsy, patients
received rescue chemotherapy as determined by their primary attending oncologist. All dogs
received a follow up full clinical examination plus CBC, CS and urinalysis one-week post
NBD peptide injection. Mass of the NBD treated lymph node and the contra-lateral,
malignant, untreated lymph node was calculated before, and one week post NBD peptide
administration.
Results
Constitutive canonical NF-κB activity occurs in dogs with DLBCL
To determine whether constitutive NF-κB activity is present in dogs with spontaneous,
histologically confirmed DLBCL, EMSA was performed on biopsy samples taken from the
peripheral lymph nodes of 13 dogs with DLBCL at the time of diagnosis and prior to
chemotherapy. Constitutive NF-κB activity was detected in all 13 samples. In contrast, NF-
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κB activity was not detected in normal lymph nodes from healthy dogs (Fig. 1A). To
determine whether constitutive NF-κB activity was associated with the canonical pathway,
malignant lymph node tissue from 11 dogs with newly diagnosed, histologically confirmed
DLBCL was analyzed by EMSA supershift using antibodies directed against p50, p65 and c-
Rel. In 7 dogs, p50, p65 and c-Rel were all present in the active NF-κB complexes (Fig. 1B).
In 2 dogs only p50 and p65 were present, and in 2 dogs only p50 was identified (data not
shown). To further confirm the presence of constitutive canonical NF-κB activity, formalin-
fixed, paraffin-embedded lymph node tissues from 6 dogs with DLBCL were evaluated for
the presence of nuclear p65 by immunohistochemistry (Fig. 1C). All tissue sections had
abundant cytoplasmic and nuclear-localized p65 whereas 4 healthy canine lymph node
sections had minimal p65 staining.
To determine whether the detected canonical NF-κB activity was associated with
constitutive IKK activity, the phosphorylation status of the IKK complex and the inhibitory
IκBα protein were evaluated by immunoblot (Fig. 1D). p-IKKβ and p-IκBα were detected in
8 out of 9 lymph node biopsy samples taken from dogs with histologically confirmed,
untreated DLBCL with constitutively active NF-κB as determined by EMSA. In contrast, p-
IKKβ and p-IκBα were only detected at very low levels in normal lymph nodes taken from
healthy dogs (Fig. 1D). Taken together, these findings demonstrate that constitutive
canonical NF-κB activity occurs in the malignant tissue of dogs with DLBCL, and that in
the majority of dogs this activity is associated with IKK activation and downstream IκBα
phosphorylation. These data parallel findings in human ABC-DLBCL, and suggest that dogs
with DLBCL represent a clinically relevant, spontaneous large animal model in which to
evaluate the therapeutic effects of NF-κB inhibition in the treatment of ABC-DLBCL.
Anti-apoptotic NF-κB target genes are up-regulated in canine DLBCL
To determine whether NF-κB target genes are up-regulated in canine DLBCL, malignant
lymph node tissue from 14 dogs with histologically confirmed DLBCL and constitutive NF-
κB activity was evaluated by qRT-PCR for Bcl-2, c-FLIP and XIAP gene expression (Fig.
2). Tissue samples were obtained at the time of diagnosis and prior to chemotherapy. Using
healthy canine lymph node tissue as a normalizing control, statistically significant increases
in Bcl-2 gene expression were identified in 7 dogs. In addition, c-FLIP and XIAP gene
expression was significantly increased in 6 and 7 dogs, respectively. These results suggest
that constitutive canonical NF-κB activity in canine DLBCL promotes the over-expression
of anti-apoptotic NF-κB target genes. This finding parallels that in human patients with
ABC-DLBCL and indicates that constitutive canonical NF-κB activity in the dog may
contribute to lymphomagenesis and chemoresistance.
NBD Peptide inhibits constitutive NF-κB activity and promotes apoptosis in DLBCL cells in
vitro
To determine whether NBD peptide can inhibit constitutive phosphorylation of IKK and
prevent downstream IκBα phosphorylation, cells from malignant lymph nodes of dogs with
DLBCL were treated in vitro with either 100μM NBD peptide or 100μM mutant peptide for
12 hours and then analyzed for the presence of p-IKKβ and p-IκBα by immunoblot (Fig. 3A
and B). Cells treated with NBD peptide showed a marked reduction of p-IKKβ compared to
untreated cells, and those treated with either mutant peptide or DMSO vehicle control. NBD
peptide treatment also resulted in complete inhibition of IκBα phosphorylation (Fig. 3B). In
contrast, treatment with mutant peptide or DMSO (vehicle control) did not inhibit IκBα
phosphorylation.
To determine the effects of NF-κB inhibition on DLBCL cell apoptosis, malignant
lymphocytes harvested from canine DLBCL tumors were treated in vitro with NBD or
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mutant peptide and analyzed by flow cytometry (Fig. 3C). After 12 hours incubation with
NBD peptide, more than 50% of DLBCL cells stained positive for Annexin-V while only
15% of cells treated with mutant peptide appeared apoptotic. Comparable results were
identified in malignant cells taken from the lymph nodes of 3 dogs with DLBCL. In contrast,
when PBMCs isolated from healthy dogs were treated with either 100μM NBD or mutant
peptide for 12 hours, less than 5% of PBMCs stained positive for Annexin-V (Fig. 3D).
Collectively, these data show that NBD peptide inhibits constitutive NF-κB activity in
canine DLBCL cells, leading to selective, rapid apoptosis of malignant cells.
To confirm a selective cytotoxic effect of NBD peptide on human ABC-DLBCL cells, OCI-
Ly10 cells and the GCB-DLBCL cell line SUDHL-6 were treated with NBD peptide for 24
hours and the percentage increase in cell death compared to untreated cells was calculated.
At 24 hours, NBD peptide induced a dose dependent increase in cell death of the ABC-
DLBCL cell line, OCI-Ly10. In contrast, NBD peptide did not induce cell death in the GCB-
DLBCL cell line at either concentration used (Fig. 3E).
In vivo administration of NBD peptide inhibits NF-κB target gene expression and leads to a
reduction in tumor burden in dogs with relapsed, chemoresistant large B-cell lymphoma
To determine whether NBD peptide can inhibit NF-κB target gene expression in malignant
lymphoid tissue in vivo, privately owned dogs with relapsed, chemoresistant large B-cell
lymphoma were enrolled to a small pilot study (Fig. 4). Eligibility criteria included the
presence of histologically or cytologically confirmed large B-cell lymphoma and
constitutive NF-κB activity in malignant lymph nodes as determined by EMSA. Response to
NBD peptide was determined by evaluating NF-κB target gene expression pre and 24 hours
post NBD peptide administration. Clinical response to NBD peptide was determined by
comparing the mass of the injected lymph node before NBD peptide and 1 week after
administration of peptide plus rescue chemotherapy. The mass of the contra-lateral
malignant lymph node that was not injected with NBD peptide but was exposed to systemic
rescue chemotherapy was also determined at both time points and the change in lymph node
mass was calculated for both nodes and compared. Six eligible dogs were enrolled to the
study, three dogs received 5mg NBD peptide/100g of node tissue and three received 10mg
NBD peptide/100g node tissue via a single intra-nodal injection. At the time of enrollment,
qRT-PCR analysis of lymph node tissue revealed that all dogs over-expressed at least 2 out
of 6 NF-κB target genes that promote cellular proliferation and inhibit apoptosis when
compared to normal lymph node tissue (Fig. 5A left panel). 24 hours post NBD peptide
administration 1 out of 3 dogs receiving 5mg NBD peptide/100g nodal tissue showed a
reduction in the expression of 4/6 NF-κB target genes within the malignant node when
compared to pre-NBD treatment gene expression values. At the higher dose of NBD peptide
all three dogs showed a reduction in the expression of at least 3/6 NF-κB target genes
including Bcl-2, Cyclin D1 and IκBα when compared to pre-NBD treatment values. (Fig. 5A
right panel).
Response to NBD peptide was determined by comparing the change in mass of the NBD
peptide treated lymph node with change in mass of the contra-lateral, malignant, non-
injected lymph node. Results were available for 4 of the 6 treated dogs (Fig. 5B). Rescue
chemotherapy protocols administered to each dog after NBD peptide treatment varied
amongst dogs and were determined by the referring oncologist. In 3 out of 4 dogs, the NBD
peptide treated lymph node showed between a 1.5 and 6 fold reduction in mass when
compared to the contra-lateral, malignant lymph node that did not receive NBD peptide.
Two dogs (dogs 7 and 8) were treated on a compassionate basis and given intranodal
injections of 10mg NBD/100g tumor into 8 peripheral enlarged lymph nodes, resulting in
cumulative NBD doses of 0.33 and 0.8 mg/kg body weight respectively. This amendment to
the original protocol was approved by the University of Pennsylvania’s Institutional Animal
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Care and Use Committee. At enrollment, each dog over-expressed at least 3 NF-κB target
genes (Fig. 5A left panel). 24 hours after NBD peptide administration, reductions in NF-κB
target gene expression were observed in 3/6 and 6/6 evaluated genes, respectively (Fig. 5A
right panel). In these two dogs, a reduction in lymph node mass was observed in 3/8 and 4/8
NBD treated lymph nodes (Fig. 5C). Despite NBD peptide and systemic chemotherapy, the
remaining lymph nodes continued to increase in size. In both dogs, the lymph nodes that
showed a reduction in mass following NBD peptide treatment were the smallest nodes at the
time of treatment.
Discussion
Aberrant, constitutive, canonical NF-κB activity is recognized as a key contributor to
oncogenesis and chemotherapy resistance in many different cancers and as such represents a
logical target for inhibition in cancer therapy. While nearly 800 inhibitors of NF-κB have
been identified, (40) their ability to inhibit constitutive NF-κB activity in spontaneous
cancers in vivo and the therapeutic relevance of such inhibition in patients with cancer is
unknown.
In this study we first set out to determine whether dogs with DLBCL represent an
appropriate, spontaneous, large animal model in which to evaluate the therapeutic effects of
NF-κB inhibition. DLBCL in the dog is often characterized by total effacement of lymph
node architecture with large malignant B-cells that have a high mitotic index and multiple,
prominent nucleoli (41). This malignancy in dogs is frequently associated with over-
expression of c-myc that occurs as a result of chromosomal translocations that place the
oncogene under control of the IgH promoter (17). While these histocytological and
cytogenetic changes are also found in ABC-DLBCL in humans, it is unknown whether
canine DLBCL is characterized by constitutive canonical NF-κB activity. Here we show that
dogs with histologically confirmed DLBCL have constitutive canonical NF-κB signaling in
malignant lymphoid tissue at the time of diagnosis. In most cases evaluated, p50/p65 and
p50/c-Rel heterodimers were present in the activated complex. Only 2 biopsy samples had
evidence of active p50 in the apparent absence of active p65 or c-Rel suggesting the
presence of p50 homodimers or complexes with RelB in these patients. These differences
may be attributed to the specific mechanism(s) responsible for constitutive NF-κB activity in
each tumor sample, as the identity and relative abundance of active homo-and heterodimers
depends on the nature of the activating signal or pathway aberrancy (42, 43). Furthermore,
as in human ABC-DLBCL patients, constitutive activity was associated with
phosphorylation of IKKβ and IκBα in all but one dog evaluated, indicating that in the
majority of cases signals leading to constitutive activity occur upstream of the IKK complex
(7, 10). These findings confirm on a molecular level that human ABC-DLBCL and canine
DLBCL have similar aberrant NF-κB signaling and that the dog may serve as a clinically
relevant large animal model in which to study the therapeutic effects of NF-κB pathway
inhibition in ABC-DLBCL.
Although constitutive NF-κB activity was present in the malignant lymph nodes of all dogs
with untreated DLBCL, the NF-κB target genes Bcl-2, c-FLIP and XIAP were over-
expressed in only half of the biopsy samples. These findings serve to underline the multiple
layers of complexity involved in the regulation of NF-κB target gene expression. Firstly, the
particular combination of activated NF-κB family members influences the target gene
expression profile, in part because these family members have different binding affinities for
different gene promoters. While NF-κB activation originates upstream of IKK in these dogs,
the specific activation triggers have not been investigated and may differ between dogs,
resulting in different NF-κB family member usage and different target gene expression
signatures. However, in this small dataset, we did not find any correlation between the
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expression of NF-κB target genes and activation of specific NF-κB family members.
Secondly, other signaling pathways that activate additional transcription factors such as
AP-1 and ETS may be concurrently active in these tumors. These transcription factors
together with co-factors that modify NF-κB activity influence gene activation and
repression, leading to variable gene expression profiles (44, 45). Taken together these points
highlight the complex and multifaceted nature of NF-κB regulated gene expression. A much
larger sample set of histologically confirmed, DLBCL biopsies with complete gene
expression profiling together with a thorough evaluation of activated NF-κB family
members will be needed to identify specific NF-κB gene expression signatures.
In the second part of this study we show that NBD peptide can inhibit constitutive IKKβ and
IκBα phosphorylation in DLBCL biopsy samples which leads to increased apoptosis of
malignant lymphocytes. Furthermore, in a small clinical pilot study NBD peptide showed a
dose-dependent inhibition of NF-κB target gene expression in dogs with relapsed, refractory
large B-cell lymphoma. In 2 dogs receiving the lower NBD peptide dose (dogs 1 and 3), all
NF-κB target genes increased up to 4-fold 24 hours post NBD peptide suggesting that
constitutive NF-κB activity in these dogs may be exerting a transcriptional repressive effect.
No correlation was identified between 24-hour gene expression profile results and change in
lymph node mass 7 days later.
In 3 out of 4 dogs, intra-nodal administration of NBD peptide led to a marked reduction in
tumor mass when compared to the contra-lateral, malignant lymph node that did not receive
NBD peptide, although it is unclear whether NBD peptide alone, or acting synergistically
with rescue chemotherapy exerted this effect. In dogs that received multi-node injections of
NBD peptide, the apparent effects on tumor mass were variable. While most nodes
continued to increase in size despite NBD treatment and rescue chemotherapy, several nodes
in both dogs showed a marked reduction in tumor mass. In both cases, responding nodes
were smaller than non-responsive nodes at the time of treatment. These results raise the
possibility that the NBD peptide dose and its ability to diffuse within malignant nodes may
influence its ability to exert a measurable therapeutic effect.
Given the central role of the IKK complex in canonical NF-κB activation, IKK inhibitors are
being investigated as novel therapeutic agents in both solid and hematological malignancies
that depend upon constitutive NF-κB activity for their survival. IKKβ inhibitors have been
developed to specifically block canonical NF-κB signaling; however, in the presence of
selective IKKβ inhibition, compensatory IKKα activity can drive NEMO-dependent
canonical NF-κB activity in human DLBCL cells (46). This finding suggests that inhibitors
of both IKKα and IKKβ activity (such as NBD peptide) will provide more complete
inhibition and have greater therapeutic efficacy than IKKβ inhibitors alone. Furthermore,
agents such as NBD peptide that specifically target the scaffolding molecule NEMO are less
likely than kinase inhibitors to exhibit off-target effects on other intracellular signaling
pathways (27).
Previous studies evaluating the safety and efficacy of NBD peptide as an anti-inflammatory
agent in vivo have shown that both short and long term administration of NBD peptide to
piglets and rodents at doses ranging from 0.75–20 mg/kg is well tolerated (24, 28–31). In
this small pilot study, NBD peptide did not cause any systemic toxicity and there were no
significant changes in serum chemistries or hematological profiles over the 10 day
assessment period that could be attributable to NBD peptide administration. However, the
dose of NBD peptide administered on a mg/kg body weight basis was very low. However, 2
dogs treated with the higher dose of NBD peptide developed submandibular abscesses
within one week of NBD injection into pre-scapular lymph nodes. In both cases, the
commensal skin bacteria Staphalococcus aureus was cultured and successfully treated with
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drainage and broad-spectrum antibiotics. In these cases it is possible that commensal skin
bacteria introduced with NBD peptide were able to colonize the necrotic node and that
inhibition of TLR signaling by NBD peptide may have contributed to this process.
In this pilot study, NBD peptide was administered intra-nodally rather than systemically to
first determine whether it could inhibit constitutive NF-κB activity in malignant
lymphocytes in vivo. Based on the favorable in vitro and in vivo results we are now actively
recruiting dogs with ABC-DLBCL to a phase I dose escalation clinical trial in which NBD
peptide will be administered systemically via the intravenous route. While the amount of
peptide necessary to achieve complete inhibition of NF-κB activity in a dog or human are
likely to be high, it is unknown whether complete inhibition is required to see a therapeutic
effect when used in combination with chemotherapy.
Taken together, the results reported here provide the first in vivo evidence that NBD peptide
can inhibit anti-apoptotic target gene expression driven by constitutive NF-κB activity and
that this inhibition, either alone or in combination with cytotoxic therapy, can lead to
improved clinical responses in dogs with ABC-like DLBCL. Given our reported findings
that demonstrate the dog is a highly relevant, spontaneous clinical model for ABC-DLBCL
in humans, the therapeutic effects of NF-κB inhibition seen in the canine cancer patient are
likely to hold high translational relevance to human patients with ABC-DLBCL.
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Statement of Translational Relevance
Activated B-Cell Diffuse Large B-Cell Lymphoma (ABC-DLBCL) is an aggressive,
poorly chemoresponsive lymphoid malignancy characterized by constitutive canonical
NF-κB activity that promotes lymphomagenesis and chemotherapy resistance via over-
expression of anti-apoptotic NF-κB target genes. We have investigated NF-κB as a
therapeutic target using the dog as a clinically relevant, spontaneous, animal model of
DLBCL. We show that as in human ABC-DLBCL, malignant lymphocytes from dogs
with DLBCL have constitutive canonical NF-κB activity and over-express anti-apoptotic
genes. We demonstrate that the selective IKK inhibitor, NBD peptide inhibits NF-κB
activity in vitro and leads to apoptosis of malignant B cells. We show in vivo that intra-
tumoral injections of NBD peptide inhibit NF-κB gene expression and reduce tumor
burden in dogs with DLBCL. These studies demonstrate the therapeutic relevance of NF-
κB inhibition in vivo in a canine DLBCL model and have important translational
relevance for the treatment of human ABC-DLBCL.
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Figure 1. Constitutive canonical NF-κB activity in dogs with spontaneous DLBCL
(A) Whole cell protein extracts of normal lymph nodes (NLN) taken from 3 healthy dogs
and lymph nodes taken from 4 dogs with primary, untreated DLBCL were evaluated for NF-
κB DNA binding activity by EMSA. Results shown are representative of 13 dogs with
DLBCL. (B) Whole cell protein extracts of lymph nodes taken from 2 dogs with primary,
untreated DLBCL were subject to EMSA supershift analysis with antibodies against p65,
p50, c-Rel, or control rabbit IgG. Results shown are representative of 7 dogs with DLBCL.
(C) Immunohistochemical staining for p65 was performed on lymph node sections from
healthy dogs and dogs with DLBCL. Rabbit IgG was used as an isotype control.
Arrowheads indicate nuclear p65 staining. Results shown are representative of 6 dogs with
DLBCL and 4 healthy dogs (NLN). (D) Whole cell protein extracts of NLN and lymph
nodes taken from 3 dogs with primary, untreated DLBCL were evaluated for the presence of
p-IKKβ and p-IKBα by Western blot. Results shown are representative of 8 dogs with
DLBCL. β-actin was used as an endogenous loading control.
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Figure 2. Expression of anti-apoptotic NF-κB target genes in canine DLBCL
RNA was isolated from lymph node biopsies of dogs with DLBCL at the time of diagnosis
and prior to chemotherapy. qRT-PCR was performed for Bcl-2, c-FLIP and XIAP. Values
are expressed as relative quantification using β-actin as an endogenous control. RNA
isolated from biopsy samples of 3 healthy canine lymph nodes were used as a normalizing
control. All data shown represent means +/− SEMs of reactions performed in triplicate.
Statistical analysis was performed using a two-tailed Student’s ‘t’ test where * p<0.05.
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Figure 3. NBD Peptide Inhibits Constitutive NF-κB Activity in Canine Primary DLBCL in vitro
Primary canine DLBCL cells were treated with either 100μM NBD peptide or mutant
peptide or with DMSO (vehicle control) for 12 hours. 25 μg of whole cell extract was
immunoblotted using antibodies against (A) p-IKKβ and pan-IKKβ and (B) p-IκBα and pan-
IκBα. β-actin was used as an endogenous loading control. Results are representative of 3
individual dogs. Canine PBMCs with or without TNF-α were included as positive and
negative controls for p-IKKβ and p-IκBα. (C) Primary canine DLBCL cells were either
untreated (grey histogram) or treated (open histograms) with either 100μM NBD peptide or
mutant peptide for 12 hours and then analyzed by flow cytometry for Annexin-V. Results
are representative of 3 individual dogs. (D) Healthy canine PBMCs were treated with
100μM NBD peptide or mutant peptide for 12 hours and then analyzed by flow cytometry
for Annexin-V. Histograms are gated on CD21+ lymphocytes. (E) OCI-Ly10 and SUDHL-6
cells were treated with 0, 25μM or 50μM NBD peptide for 24 hours. Cell death was
quantified by Trypan Blue. Data represent the percent increase in cell death in treated wells
compared to untreated cells. Cell counts were performed in triplicate, and data shown
represents means +/− SEMs. Statistical analysis was performed using a two-tailed Student’s
‘t’ test. *p<0.05. Results are representative of 3 separate experiments.
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Schematic of Pilot Clinical Trial.
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Figure 5. In vivo administration of NBD peptide inhibits NF-κB target gene expression in
malignant lymph nodes of dogs with relapsed/resistant large B-Cell lymphoma
(A; left panel) qRT-PCR of malignant lymph nodes of dogs with relapsed large B-Cell
lymphoma at enrollment. Values are expressed as relative quantification using β-actin as an
endogenous control. RNA isolated from biopsy samples of 3 healthy canine lymph nodes
were used as a normalizing control. (A; right panel) qRT-PCR of malignant lymph nodes 24
hours post NBD peptide injection. RNA isolated from biopsy samples of the same dogs prior
to NBD peptide treatment was used as a normalizing control. All data shown represents
means +/− SEMs of reactions performed in triplicate. (B) Comparison of percent decrease in
mass between NBD injected lymph node and contra-lateral, malignant, non-injected lymph
node of 4 study dogs. Measurements were taken immediately prior to and one week post
NBD peptide administration. (C) Percent decrease in mass of NBD injected lymph nodes
from 2 dogs that received multi-nodal injections of NBD peptide.
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